Last viewed:
NVO
Prices are updated after-hours
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
(0.0% 1d)
(-5.5% 1m)
(-28.9% 1y)
(0.0% 2d)
(-1.5% 3d)
(-1.0% 7d)
(68.56%
volume)
Earnings Calendar:
Market Cap: $ 421,524,556,880
http://www.novonordisk.com
Sec
Filling
|
Patents
| 43258 employees
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
obesity
diabetes
haemophilia
insulin
diabetic
hormone
growth hormone
add to watch list
Paper trade
email alert is off
Press-releases
Peptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19
(Crawled : 15:00)
- prnewswire.com
AZNCF
|
News
|
$138.24
-4.19%
800
|
Health Technology
| 0.66%
| O: 0.24%
H: 0.42%
C: 0.42%
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -1.46%
| O: -0.84%
H: 0.86%
C: -0.62%
GSK
|
News
|
$39.75
1.22%
0.0%
1.6M
|
Health Technology
| 0.38%
| O: -0.58%
H: 0.99%
C: 0.97%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
| -3.26%
| O: -0.21%
H: 0.11%
C: -3.05%
AZN
|
News
|
$68.56
0.29%
0.29%
4.7M
|
Health Technology
| 0.42%
| O: -0.18%
H: 0.84%
C: 0.6%
report
reach
therapeutics
market
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17
(Crawled : 14:00)
- biospace.com/
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -0.6%
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02
trial
therapeutics
results
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2024-04-15
(Crawled : 18:00)
- globenewswire.com
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -1.45%
| O: 1.04%
H: 0.19%
C: -1.52%
Novo Nordisk A/S - share repurchase programme
Published: 2024-04-15
(Crawled : 13:00)
- globenewswire.com
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -1.45%
| O: 1.04%
H: 0.19%
C: -1.52%
repurchase
Novo Nordisk A/S - share repurchase programme
Published: 2024-04-08
(Crawled : 13:30)
- globenewswire.com
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -1.81%
| O: 1.62%
H: 0.5%
C: 0.36%
repurchase
Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-08
(Crawled : 12:30)
- biospace.com/
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -1.81%
| O: 1.62%
H: 0.5%
C: 0.36%
conference
therapeutics
REDUCED secures EUR 6 million financing led by Novo Holdings to scale its natural food ingredients business
Published: 2024-04-04
(Crawled : 06:00)
- prnewswire.com
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -2.23%
| O: 1.1%
H: 0.46%
C: -2.32%
business
natural
million
food
2023 Novo Holdings Asia Investments Annual Review/Business Update
Published: 2024-04-03
(Crawled : 07:00)
- prnewswire.com
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -2.97%
| O: -0.75%
H: 0.0%
C: 0.0%
investments
update
asia
Novo Nordisk A/S - share repurchase programme
Published: 2024-04-02
(Crawled : 11:00)
- globenewswire.com
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -3.79%
| O: -1.96%
H: 1.3%
C: 1.13%
repurchase
Novo Nordisk A/S - share repurchase programme
Published: 2024-03-25
(Crawled : 12:00)
- globenewswire.com
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
| -4.7%
| O: 0.19%
H: 0.97%
C: 0.04%
repurchase
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount